Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation

Immunologic Research

Volumn 22, Issue 2-3, 2000, Pages 319-341

  Weinberg, J B ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Inflammation; Macrophage; Monocyte; Nitric oxide; Prostaglandin; Rheumatoid arthritis

Indexed keywords

ALPHA INTERFERON; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INFLAMMATION; MALARIA; MECHANICAL STRESS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; RNA TRANSCRIPTION;

ANIMALS; ANTIBODIES; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2; HUMANS; INFLAMMATION; INTERFERON-ALPHA; ISOENZYMES; LEUKOCYTES, MONONUCLEAR; MEMBRANE PROTEINS; MICE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034449920     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:22:2-3:319     Document Type: Conference Paper

References (178)

1. Cellularbasis for rheumatoid inflammation
2. Rheumatoid arthritis. Pathophysiology and implications for therapy
3. Pathogenesis of rheumatoid arthritis
4. Cytokines in autoimmunity
5. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colonystimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha
6. Interleukins, interferon and rheumatic disease
7. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis
8. The L-arginine-nitric oxide pathway
9. Nitric oxide as a secretory product of mammalian cells
10. Pathological implications of nitric oxide, superoxide and peroxynitrite formation. [Review]
11. Nitric oxide modulation of human leukemia cell differentiation and gene expression
12. Production of nitric oxide by murine-bone marrow cells. Inverse correlation with cellular proliferation
13. Biochemistry of nitric oxide and its redox-activated forms
14. Induction of nitric oxide synthase in human chondrocytes
15. Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte
16. Nitric oxide synthase-Expression of the endothelial, Ca2+/calmodulin-dependent in human B and T lymphocytes
17. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Bart virus reactivation
18. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity
19. Nitric oxide synthesis and its regulation by rabbit synoviocytes
20. Regulation of biosynthesis of nitric oxide
21. Characterization and functional analysis of the human inducible nitric oxide synthase gene promoter
22. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines-initial analysis of the human NOS2 promoter
23. Multiple NF-kappa-B enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene
24. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene
25. Cytokine induction of NO synthase 11 in human DLD-1 cells: Roles of the JAK-STAT, AP-1 and NF-kappaB-signaling pathways
26. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages
27. Autocrine/paracrine IFN-alpha/beta mediates the lipopolysaccharide-induced activation of transcription factor Statlalpha in mouse macrophages: Pivotal role of Stat1alpha in induction of the inducible nitric oxide synthase gene
28. Complex contribution of the 3′-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene - Involvement of the RNA-binding protein HuR
29. Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle
30. Feedback inhibition of nitric oxide synthase activity by nitric oxide
31. Constitutive nitric oxide synthase from cerebellum is reversibly inhibited by nitric oxide formed from L-arginine
32. Human monocytes/macrophages: NO or no NO?
33. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS). Analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages
34. Nitric oxide production and nitric ox[de synthase type 2 expression by human mononuclear phagocytes: A review
35. Induction of cyclooxygenase and nitric oxide synthase in inflammation
36. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
37. New insights into the role of COX 2 in inflammation
38. Cyclooxygenase knockout mice - Models for elucidating isoform-specific functions [Review]
39. Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression
40. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages
41. Regulation by prostaglandin E2 of cytokine-elicited nitric oxide synthesis in rat liver macrophages
42. Modulation of the induction of nitric oxide synthase by eicosanolds in the murine macrophage cell line J774
43. Nitric oxide production from macrophages is regulated by arachidonic acid metabolites
44. Cross-talk between cyclooxygenase and nitric oxide pathways prostaglandin E2 negatively modulates induction of nitric oxide synthase by interleukin 1
45. Prostaglandin E2 regulates inducible nitric oxide synthase in the murine macrophage cell line J774
46. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells
47. Nitric oxide activates cyclooxygenase enzymes
48. Co-induction of nitric oxide synthase and cyclo-oxygenase: Interactions between nitric oxide and prostanoids
49. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation
50. Dual inhibition of nitric oxide and prostaglandin production contributes to the anti-inflammatory properties of nitric oxide synthase inhibitors
51. The mode of action of aspirin-like drugs effect on inducible nitric oxide synthase
52. Repression of inducible nitric oxide synthase and cyclooxygenase-2 by prostaglandin E2 and other cyclic AMP stimulants in J774 macrophages
53. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide
54. Interactions of nitric oxide with cyclooxygenase: In vitro, ex vivo, and in vivo studies
55. Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors
56. Modulation by nitric oxide of prostaglandin biosynthesis in the rat
57. Regulatory interactions between inducible nitric oxide synthase and eicosanoids in glomerular immune injury
58. Role of nitric oxide in eicosanoid synthesis and uterine motility in estrogen-treated rat uteri
59. Regulation of the inducible cyclo-oxygenase pathway in human cultured airway epithelial (A549) cells by nitric oxide
60. Nitric oxide produced by endothelial ceils increases production of eicosanolds through activation of prostaglandin H synthase
61. Nitric oxide: A prostaglandin H synthase 1 and 2 reducing cosubstrate that does not stimulate cyclooxygenase activity or prostaglandin H synthase expression in murine macrophages
62. Nitric oxide synthase/COX cross-talk: Nitric oxide activates COX-1 but inhibits COX-2derived prostaglandin production
63. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase
64. Interaction between nitric oxide and prostaglandin H synthase
65. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes
66. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases
67. Monocyte activation in early onset rheumatoid arthritis
68. The peroxisome proliferator-activated receptor gamma (PPAR gamma) as a regulator of monocyte/macrophage function
69. The RXR heterodimers and orphan receptors
70. Inflammation. Signalling the fat controller
71. The PPAR alpha-leukotriene B4 pathway to inflammation control
72. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
73. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
74. Expression of the peroxisome proliferator-activated receptor gamma (PPAR-gamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
75. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
76. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs
77. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase
78. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation
79. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: Increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine
80. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J(2) and proliferator activation receptor-gamma agonists
81. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heine oxygenase 1
82. Feedback control of cyclooxygenase-2 expression through PPAR gamma
83. Activation ofproliferatoractivated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
84. 15-Deoxy-Delta(12,14)-prostaglandin J(2) inhibits multiple steps in the NF-kappa B signaling pathway
85. 15-Deoxy-delta(12,14)PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
86. Nitric oxide-a novel mediator of inflammation [Review]
87. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation
88. Nitric oxide and its role in orthopaedic disease [Review]
89. The effects of the nitric oxide donors molsidomine and SIN-1 on human polymorphonuclear leucocyte function in vitro and ex vivo
90. Nitric oxide: An endogenous modulator of leukocyte adhesion
91. The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders
92. Suppression of lymphocyte proliferation through the nitric oxide synthesizing pathway
93. Nitric oxide suppression of human hematopoiesis in vitrocontribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha
94. Differential effects of nitric oxide on erythroid and myeloid colony growth from CD34(+) human bone marrow cells
95. Translational regulation via iron-responsive elements by the nitric oxide/NO-synthase pathway
96. Biosynthesis of nitric oxide activates iron regulatory factor in macrophages
97. Nitric oxide and arthritis
98. Nitric oxide as aa inflammatory mediator in autoimmune MRL-lpr/lpr mice
99. Nitric oxide production in relation to spontaneous B-Cell lymphoma and myositis in SJL mice
100. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta-1 null mouse
101. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta
102. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases
103. Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone
104. Elevated nitric oxide production in rheumatoid arthritis-detection using the fasting urinary nitrate/creatinine ratio
105. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation-nitrotyrosine in serum and synovial fluid from rheumatoid patients
106. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides
107. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients
108. Increased nitric oxide levels in patients with rheumatoid arthritis
109. Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients
110. Prostaglandins and inflammation
111. Induction of cyclooxygenase-2 on activated T lymphocytes: Regulation of T cell activation by cyclooxygenase-2 inhibitors
112. Regulatory effects of prostaglandin E2 on the growth and differentiation of human B lymphocytes activated through their CD40 antigen
113. Prostaglandin E2 and cAMP inhibit B lymphocyte activation and simultaneously promote IgE and IgG1 synthesis
114. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease
115. Fas and Fas ligand: Lpr and gld mutations
116. Functional alterations of macrophages in autoimmune MRL-lpr/lpr mice
117. Thromboxane receptor blockade reduces renal injury in murine lupus nephritis
118. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
119. EPR characterization of molecular targets for NO in mammalian cells and organelles
120. Nitrosylation of blood hemoglobin and renal nonheme proteins in autoimmune MRL-lpr/lpr mice
121. Peroxynitrite and decreased catalase in autoimmune mice
122. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry
123. Evidence for in vivo peroxynitrite production in human acute lung injury
124. Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury
125. Genotype effects on the antioxidant enzymes activity and mRNA expression in liver and kidney tissues of autoimmune-prone MRL/MpJ-lpr/lpr mice
126. A spontaneous rheumatoid arthritis-like disease in MRL-1 mice
127. The genetics of autoantibody production in MRL/lpr lupus mice
128. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2
129. IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis
130. Some misconceptions about understanding autoimmunity through experiments with knockouts
131. Attenuation of collagen-induced arthritis in 55kDa TNF receptor type 1 (TNFR1)IgG1-treated and TNFR1-deficient mice
132. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
133. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF alpha treatment
134. Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained Bcl-2 levels
135. Nitric oxide-stimulated guanine nucleotide exchange on p21(Ras)
136. The induction of nitric oxide synthase activity is inhibited by TGF-β1, PDGF-AB and PDGF-BB in vascular smooth muscle cells
137. Mechanisms of nitric oxide-related antimicrobial activity
138. Proposed link between cytokines, nitric oxide, and human cerebral malaria
139. Nitric oxide in Tanzanian children with malaria. Inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression
140. Effects of age and parasitemia on nitric oxide production/leukocyte nitric oxide synthase type 2 expression in asymptomatic, malaria-exposed children
141. Nitric oxide, malaria, and anemia: Inverse relationship between nitric oxide production and hemoglobin concentration in asymptomatic, malaria-exposed children
142. Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity inTanzanian children with malaria
143. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria
144. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria
145. Evolution of a homopurine-homopyrimidine pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene
146. Hepatitis C [Review]
147. Pathogenesis of influenza viresinduced pneumonia: Involvement of both nitric oxide and oxygen radicals
148. Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication
149. Inhibition of vesicular stomatitis virus infection by nitric oxide
150. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase
151. Inhibition of viral replication by nitric oxide and its reversal by ferrous sulfate and tricarboxylic acid cycle metabolites
152. Nitric oxide inhibits viral replication in murine myocarditis
153. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase
154. The antiviral role of nitric oxide
155. Inhibition of nitric oxide synthesis increases mortality in Sindbis virus encephalitis
156. Interferon (IFN)alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression - Possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo
157. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production
158. IFN-alpha beta reconstitutes the deficiency in lipid A-activated AKR macrophages for nitric oxide synthase
159. Exogenous interferongamma induces endogenous synthesis of interferon-alpha and -beta by murine macrophages for induction of nitric oxide synthase
160. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron
161. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C
162. Iron stores, respouse to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C
163. Iron regulates nitric oxide synthase activity by controlling nuclear transcription
164. Systemic lupus erythematosus diagnosed during interferon alfa therapy
165. Rheumatoid arthritis: A complication of interferon therapy
166. Immune-mediated side-effects of cytokines in humans
167. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders
168. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment
169. Interferon-beta 1A-induced polyarthritis in a patient with the HLA-DRB 1*0404 allele
170. Cytokine concentrations in the synovial fluid and plasma of rheumatoid arthritis patients: Correlation with bony erosions
171. Acid labile alpha-interferon in sera and synovial fluids from patients with juvenile arthritis
172. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon
173. The role of cytokines in the pathogenesis of rheumatoid arthritis
174. Anticytokine therapy for rheumatoid arthritis
175. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2)
176. The effects of static and dynamic compression on nitric oxide production in articular cartilage explants
177. The effects of dynamic mechanical compression on nitric oxide production in the meniscus